variables: 817003
Data license: CC-BY
This data as json
id | name | unit | description | createdAt | updatedAt | code | coverage | timespan | datasetId | sourceId | shortUnit | display | columnOrder | originalMetadata | grapherConfigAdmin | shortName | catalogPath | dimensions | schemaVersion | processingLevel | processingLog | titlePublic | titleVariant | attributionShort | attribution | descriptionShort | descriptionFromProducer | descriptionKey | descriptionProcessing | licenses | license | grapherConfigETL | type | sort | dataChecksum | metadataChecksum |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
817003 | Bacteriologically confirmed pulmonary tuberculosis patients with rifampicin susceptibility who are HIV-positive | patients | 2023-12-05 11:52:00 | 2024-07-25 22:54:11 | 2017-2019 | 6308 | { "unit": "patients", "numDecimalPlaces": 0 } |
0 | nrr_hivpos | grapher/tuberculosis/2023-11-27/drug_resistance_surveillance/drug_resistance_surveillance#nrr_hivpos | 2 | major | Number of bacteriologically confirmed pulmonary tuberculosis patients with rifampicin susceptibility who are HIV-positive. Rifampicin is an antibiotic medication used primarily in the treatment of tuberculosis and other bacterial infections; it works by inhibiting the growth of bacteria. | Among new and previously treated patients that have confirmed pulmonary tuberculosis cases with results for rifampicin testing, the number susceptible to rifampicin and who are HIV-positive. | [] |
int | [] |
370861c55b23cfbc7c5e96d4f7b7720a | ae13882455434f3021cb628587cc77e1 |